Board of Directors
Ying Luo, PhD
Dr. Luo received his doctorate in molecular biology/biomedical sciences from the University of Connecticut Health Center in 1991. He later studied HIV gene regulation in UCSF as a postdoctoral fellow. Prior to founding Shanghai Genomics in 2001, Dr. Luo held various positions at the San Francisco Bay Area biotech firms, including Aviron, Clonetech, and Rigel. Later Shanghai Genomics was acquired by GNI Group and became listed on the Tokyo Stock Exchange Mothers Board in 2007. He is currently President and CEO of GNI Group. The pre-clinical, clinical, and regulatory teams recruited and supervised by him has successfully gained 6 IND approvals and conduct Phase I/II trials in China or US. Under his leadership, GNI Group had its first Class 1 drug Etuary® approved by China FDA in treating IPF in 2011 through expedited review process. Later he built a nationwide orphan drug sales network in China. Recently, he also engineered several acquistions for GNI, including Beijing Continent and Berkeley Advanced Biomaterials, and investments into other joint ventures. In his career of 30 years, Dr. Luo has co-authored more than 35 research publications and been inventors of more than 16 patents.
Thomas Eastling has over 30 years' experience in global finance, M&A and business development, with a substantial part of his career in Asia. He started on Wall Street at Nikko Securities Co. International, Inc., rising to the position of Senior Vice President & General Manager of the Investment Banking and Syndicate Divisions. In the late 1990's, he moved to Japan as Company Representative for Duff & Phelps Credit Rating Co. and subsequently worked as Managing Director for Softbank Corp. in strategic planning and investor relations. In 2009 he relocated to Hong Kong with American Appraisal where he served as Director of the firm's Transaction Advisory Services in Asia. In September of 2013, Mr. Eastling returned to Japan in his current role as Executive Officer of GNI Group Ltd. Mr. Eastling has a Bachelor's degree from the University of Southern California and a Masters from the American Graduate School of International Management. He speaks Japanese and is pursuing Mandarin. He currently serves as Non-Executive Director for a Hong Kong private equity fund.
Yue Xiong, PhD
Dr. Xiong finished his undergraduate at Fudan University in 1982 and Ph.D from University of Rochester in 1989. After completing a Ph.D. Postdoctoral fellowship at Cold Spring Harbor Lab, from 1993 up to now, Dr. Xiong joined Department of Biochemistry & Biophysics at University of North Carolina at Chapel Hill as a William R. Kenan Professor. He was awarded Pew Scholar Award (1995), American Cancer Society Junior Faculty Research Award (1995), AACR-Gertrude B. Elion Cancer Research Awards (1999), UNC Hettleman Award for Scholarly Achievement (1999), UNC Battle Distinguished Cancer Research Award (2011), Elected Fellow, American Association for Advancement of Science (2012). To date, Dr. Xiong has published more than 160 research papers in peer-reviewed publication and granted two US patents.
Jian Jin, PhD
Dr. Jian Jin is currently a Professor in the Departments of Pharmacological Sciences and Oncological Sciences, and the Director of the Center for Chemical Biology and Drug Discovery at Icahn School of Medicine at Mount Sinai (Mount Sinai). Dr. Jin is a medicinal chemistry expert with more than 20 years of experience in small-molecule drug discovery in both academia and industry. Prior to joining Mount Sinai in 2014, Dr. Jin was an Associate Professor at the University of North Carolina at Chapel Hill (UNC). He had also served as an Associate Director of medicinal chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Before his academic career at Mount Sinai and UNC, Dr. Jin had more than 10 years of industry experience in drug discovery at GlaxoSmithKline. For last several years, Dr. Jin’s lab has discovered multiple first-in-class small molecules that selectively degrade target proteins. These novel NCEs are potent, selective, bioavailable and efficacious in vivo.